NUVB — Nuvation Bio Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1811063 ·
Last close
$5.81
Market Cap
$2.02B
52W High
$6.60
52W Low
$4.07
ADV30
7,719,231
Next earnings
2026-05-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 83,228,000 | 77,237,000 | 3,881,000 | 5,397,000 | 610,241,000 | 125,391,000 | 290,677,000 |
| Dec 2025 | 41,865,000 | 40,586,000 | -34,037,000 | -36,592,000 | 594,822,000 | 164,086,000 | 289,106,000 |
| Sep 2025 | 13,120,000 | 9,771,000 | -56,434,000 | -55,792,000 | 601,561,000 | 98,897,000 | 275,679,000 |
| Jun 2025 | 4,833,000 | 2,257,000 | -63,589,000 | -59,007,000 | 647,225,000 | 247,970,000 | 274,318,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-125,731,000
Investing CF
$1,702,000
Financing CF
$202,031,000
CapEx
$-8,330,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,109,973,000
Inventory
$15,844,000
Receivables
$25,984,000
ST Investments
$408,338,000
EBIT TTM
$-125,658,000
Pretax Income TTM
$-145,994,000
Interest Exp TTM
$20,336,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$143,046,000
EBITDA
$-148,214,000
Free Cash Flow
$-100,037,872
Enterprise Value
$1,810,769,024
Total Cash
$533,728,992
Total Debt
$216,984,000
Shares Out
347,201,971
Trailing EPS
$-0.43
Book Value
$0.92
ROE
-39.5%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,902,000 | -213,064,000 | -204,627,000 | 594,822,000 | 289,106,000 | — | -173,427,000 |
| Dec 2024 | 7,873,000 | -167,557,000 | -567,939,000 | 540,626,000 | 76,838,000 | — | -130,413,000 |
| Dec 2023 | 0 | -99,822,000 | -75,802,000 | 621,484,000 | 16,362,000 | — | -67,999,000 |
| Dec 2022 | 0 | -119,734,000 | -104,199,000 | 672,141,000 | 17,065,000 | — | -96,108,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | $2.03B | $15.78 | — |
| SRPT | Sarepta Therapeutics, Inc. | $2.00B | $18.95 | — |
| NBTX | Nanobiotix S.A. | $2.03B | $40.07 | — |
| RAPP | Rapport Therapeutics, Inc. | $2.00B | $41.75 | — |
| SION | Sionna Therapeutics, Inc. | $2.04B | $45.29 | — |
News headlines (Yahoo Finance, 1h cache)
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
2026-07-06 21:09 · Yahoo
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?
2026-07-02 05:12 · Yahoo
Doctor-turned-dealmaker reveals his M&A playbook
2026-07-01 09:05 · Yahoo
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
2026-06-29 23:39 · Yahoo
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
2026-06-29 12:22 · Yahoo
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
2026-06-29 12:00 · Yahoo
Correction: Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks
2026-06-26 13:58 · Yahoo
Exchange-Traded Funds, Equity Futures Decline Pre-Bell Friday as Investors Shift Focus From Middle East to Technology Stocks
2026-06-26 13:11 · Yahoo
Nuvation Bio Prices $250 Million Convertible Bond Offering
2026-06-26 08:22 · Yahoo
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
2026-06-26 03:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.